Minerva Neurosciences Q1 net loss widens to $125.4 million

• Minerva Neurosciences posted a GAAP net loss of USD 125.4 million, or USD 2.86 per share, for first-quarter 2026, versus a net loss of USD 3.8 million, or USD 0.50 per share, a year earlier.
• Operating loss widened to USD 16.7 million as R&D expenses climbed to USD 5.3 million from USD 1.4 million; G&A expenses rose to USD 11.4 million from USD 2.5 million.
• Loss was weighed by a non-cash expense of USD 109.4 million tied to changes in fair value of warrant liability and losses on warrant exercises.
• Cash, cash equivalents, marketable securities, restricted cash totaled USD 78.2 million at March 31, down from USD 82.4 million at Dec. 31.
• Roluperidone confirmatory Phase 3 trial for negative symptoms of schizophrenia began in first quarter, with first patient screened in March; topline efficacy data expected in second half of 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Minerva Neurosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605050800OMX_____CNEWS_EN_GNW9712841_en) on May 05, 2026, and is solely responsible for the information contained therein.